GSK’s Nucala (mepolizumab) Receives European Commission Approval for Self-Administration in Severe Eosinophilic Asthma

 GSK’s Nucala (mepolizumab) Receives European Commission Approval for Self-Administration in Severe Eosinophilic Asthma

GSK’s Nucala (mepolizumab) Receives European Commission Approval for Self-Administration in Severe Eosinophilic Asthma

Shots:

  • The Nucala has received EMA’s marketing authorization for its new methods of administration i.e, a pre-filled pen and a pre-filled safety syringe with their anticipated launch in Europe in Aug’2019
  • The MAA is based on two P-IIIa studies (NCT03099096 & NCT03021304) which demonstrated that patients were able to administer Nucala with the pre-filled pen and pre-filled safety syringe after training (98% & 100%) respectively
  • Nucala (mepolizumab) is a once-monthly anti-IL5 biologic and is an approved therapy in the US, Europe, and other 20+ countries as an add-on maintenance treatment for SEA, currently being evaluated for the hypereosinophilic syndrome, nasal polyposis and COPD

Click here to­ read full press release/ article | Ref: GSK | Image: Business Today

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post